

ACCEPTED VERSION

O'Callaghan, Michael E.; MacLennan, Alastair Harvey

[Brain damage and maternal medication](#)

American Journal of Obstetrics and Gynecology, 2013; 208(2):160-161

© 2013 Mosby, Inc. All rights reserved.

NOTICE: this is the author's version of a work that was accepted for publication in *American Journal of Obstetrics and Gynecology*. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in American Journal of Obstetrics and Gynecology, 2013; 208(2):160-161.

DOI: [10.1016/j.ajog.2012.11.022](https://doi.org/10.1016/j.ajog.2012.11.022)

PERMISSIONS

<http://www.elsevier.com/journal-authors/policies/open-access-policies/article-posting-policy>

Elsevier's AAM Policy: Authors retain the right to use the accepted author manuscript for personal use, internal institutional use and for permitted scholarly posting provided that these are not for purposes of **commercial use** or **systematic distribution**.

Elsevier believes that individual authors should be able to distribute their AAMs for their personal voluntary needs and interests, e.g. posting to their websites or their institution's repository, e-mailing to colleagues. However, our policies differ regarding the systematic aggregation or distribution of AAMs to ensure the sustainability of the journals to which AAMs are submitted. Therefore, deposit in, or posting to, subject-oriented or centralized repositories (such as PubMed Central), or institutional repositories with systematic posting mandates is permitted only under specific agreements between Elsevier and the repository, agency or institution, and only consistent with the publisher's policies concerning such repositories.

10 February 2014

<http://hdl.handle.net/2440/78690>

Brain Damage and Maternal Medication

Dear Sir,

The paper by Tyler *et al*¹ provides novel data on the important issue of brain damage and maternal medication on which currently there is little published literature.

The authors report a positive association between maternal aspirin use during pregnancy and quadriplegia and between maternal NSAIDs use during pregnancy and quadriplegia and diplegia in infants delivered very preterm¹. Tyler *et al*'s discussion highlights the possibilities for confounding by indication and the need for replication in larger cohorts.

Using an already recruited cerebral palsy cohort² we were able to replicate part of these analyses in 145 quadriplegics, 149 diplegics and 191 hemiplegics, a cohort with 3-11 times the number of each cerebral palsy subtype reported by Tyler *et al* but recruited from deliveries at all gestational ages. Our cohort had insufficient power to independently replicate the associations reported by Tyler *et al* in very preterm infants (68 cases of cerebral palsy born at <28 weeks) but for all gestational ages no association was apparent with Aspirin and NSAID use and cerebral palsy outcomes.

In contrast, we report negative associations of maternal antibiotic use with diplegia and hemiplegia (see table 1) which was unexpected as perinatal infection is a risk factor for cerebral palsy³.

Retrospective analysis of rare outcomes such as cerebral palsy is required to achieve large sample sizes. Our data was collected using a maternal health questionnaire administered at the time of participation and may be subject to recall bias. Time between birth and study participation may account for the low reported use of Aspirin and NSAIDs compared to the report of Tyler *et al*. Our analysis adjusts for similar, but not identical confounders. It is possible that NSAID and Aspirin use is higher amongst mothers who deliver very preterm infants when compared to mothers delivering at term. The interesting results of Tyler *et al* described in infants born before 28 weeks may not generalize to cerebral palsy children born at later gestational ages.

The question of over-the-counter medications and cerebral palsy is difficult to answer as prospective studies with high quality data provide small samples, yet larger cohorts from retrospective studies provide less reliable data.

DISCLOSURE: The authors report no conflict of interest.

(357/400 words)

ME O'Callaghan, PhD

AH MacLennan, MD

Discipline of Obstetrics and Gynaecology, School of Paediatrics and Reproductive Health, Robinson Institute, The University of Adelaide, Australia.

1. Tyler CP, Paneth N, Allred EN, et al. Brain damage in preterm newborns and maternal medication: The elgan study. *Am J Obstet Gynecol* 2012;207:192 e1-9.
2. O'callaghan ME, Maclennan AH, Gibson CS, et al. The australian cerebral palsy research study-- protocol for a national collaborative study investigating genomic and clinical associations with cerebral palsy. *J Paediatr Child Health* 2011;47:99-110.
3. Wu YW, Colford JM. Chorioamnionitis as a risk factor for cerebral palsy: A meta-analysis. *JAMA* 2000;284:1417-24.

Table 1. Maternal medications and association with cerebral palsy subtypes

Maternal Medication	Controls (1,154)	Quadriplegia (145)		Diplegia (149)		Hemiplegia (191)		All CP Cases (587)	
		n (%)	n (%)	OR (95% CI), p value	n (%)	OR (95% CI), p value	n (%)	OR (95% CI), p value	n (%)
Antibiotics	58 (5)	7 (4.8)	0.3 (0.09-1.01), 0.052	11 (7.4)	0.17 (0.06-0.52), 0.002	15 (7.9)	0.17 (0.07-0.41), < 0.001	40 (6.8)	4.08 (2.08-8), < 0.001
Aspirin	4 (0.3)	0 (0)	-	1 (0.7)	-	1 (0.5)	-	5 (0.9)	0.94 (0.11-8.18), 0.95
NSAIDs	9 (0.8)	1 (0.7)	1.57 (0.11-22.4), 0.74	1 (0.7)	1.6 (0.11-22.97), 0.73	3 (1.6)	0.41 (0.1-1.69), 0.217	9 (1.5)	1.41 (0.4-4.91), 0.59
Paracetamol	265 (23)	25 (17.2)	1.26 (0.68-2.33), 0.465	29 (19.5)	0.7 (0.4-1.23), 0.215	51 (27)	0.66 (0.44-1.01), 0.056	125 (22)	1.25 (0.91,1.72), 0.17

* Adjusted for gestational age, birth weight centile and evidence of maternal infection in perinatal notes.